Rigel Pharmaceuticals has announced that Veppanu (vepdegestrant) is now available by prescription in the United States for adults with ER+/HER2-, ESR1‑mutated advanced or metastatic breast cancer. The treatment is authorised for patients whose disease has progressed after at least one line of endocrine therapy.
Veppanu is the first FDA‑approved PROTAC and is designed to selectively degrade disease‑causing proteins. Rigel said the recommended dosage is 200 mg taken orally once daily. The medicine is available through the company’s specialty distributors and pharmacies in the US and Puerto Rico at $29,400 per 30‑day supply.
Raul Rodriguez, Rigel’s president and CEO, said: “The commercial launch of VEPPANU marks an important milestone for Rigel and, more importantly, for patients living with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.”
He added: “In a pivotal trial, VEPPANU was generally well tolerated and demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus fulvestrant in this patient population.”
Rodriguez explained: “As the first and only FDA-approved PROTAC, VEPPANU introduces a novel mechanism of action and represents an important new treatment option for healthcare providers to consider with their patients.”
Rigel said Veppanu is supported by its oncology infrastructure, commercial and medical affairs teams and patient support programmes. The company’s Rigel Onecare centre offers assistance with insurance navigation, financial support for eligible patients and additional services.
More information on ordering Veppanu is available at the Rigel Onecare website. The company said Veppanu can be accessed through its network of specialty distributors and pharmacies.
Rigel entered an exclusive global licence agreement with Arvinas and Pfizer in May 2026 to develop, manufacture and commercialise Veppanu.
